Apollomics (NASDAQ:APLM) Trading Up 1.8% – Here’s What Happened

Apollomics Inc. (NASDAQ:APLM)’s stock price rose 1.8% during trading on Friday . The stock traded as high as $14.79 and last traded at $14.25. Approximately 19,128 shares changed hands during trading, an increase of 125% from the average daily volume of 8,505 shares. The stock had previously closed at $14.00.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Apollomics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Apollomics Stock Up 1.8%

The stock has a 50 day moving average price of $14.51 and a two-hundred day moving average price of $17.29.

Hedge Funds Weigh In On Apollomics

An institutional investor recently bought a new position in Apollomics stock. Kestra Advisory Services LLC bought a new position in shares of Apollomics Inc. (NASDAQ:APLM) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned 0.40% of Apollomics at the end of the most recent quarter. Hedge funds and other institutional investors own 19.13% of the company’s stock.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.